Interim Report! Sales of Cinda products increased by 10% and commercial product portfolio increased to 7; Luye Pharmaceutical made a profit of 297 million yuan

Sales of Cinda Biologics increased by 10% and the commercial product portfolio is expected to increase to 8 in the second half of 2022; Luye Pharmaceutical made a profit of 297 million yuan, and the 9 main products have established a strong competitive advantage in the field of high-incidence diseases in the world.
.
.
In this issue, Xiao G provides an overview of the highlights of the 2022 interim reports released by the two companies for the reference
of interested friends in the industry.

INNOVENT

Cinda Bio Interim Report

Revenue increased 15.
3% and product sales increased by 10%

On September 29, Innovent Bio released its 2022 interim report
.
In the six months ended June 30, 2022, the company's revenue totaled 2.
24 billion yuan, an increase of 15.
3% year-on-year; Among them, the product sales revenue was 2.
04 billion yuan, an increase of 10%
year-on-year.
The core product Daboshu (Xindilizumab) has dropped significantly due to its inclusion in the national medical insurance catalogue, and the rapid growth of product sales has also increased, coupled with the increase in the contribution of new product revenue, which has jointly driven the overall growth
of product revenue.
However, in the second quarter of 2022, due to the recurrence of the COVID-19 epidemic in Chinese mainland and the relevant epidemic prevention measures of the government, the market demand and product sales in several relevant regions and cities were restricted to a certain extent, which partly affected the growth rate
of products.

Source: Shine Bio 2022 Interim Report

During the reporting period, Cinda Bio's R&D expenditure was 1.
0777 billion yuan, an increase of 22.
5%
year-on-year.
The steady increase in R&D expenditure is mainly used for products in the late stages of development and clinical trials of priority development products in the company's global pipeline of research pipelines
.

During the 2022 reporting period and until the date of this announcement, Cinda Biologics' commercial product portfolio has increased to seven varieties
with the approval of Remosizumab in China 。 A number of products have been approved in more regions or more indications, including: Dabosco (Xindilizumab injection) has been approved by two first-line major indications of first-line ESCC and first-line GC; Dabertan (Pemitinib tablets) was approved for listing in the Chinese mainland and Hong Kong markets; Dayoutong (Indonesian trademark: Bevagen) has been approved by the Indonesian Food and Drug Administration (BPOM) and is expected to become the first Chinese antibody drug
to be commercially and locally produced in the Southeast Asian market.
In the second half of 2022, the RET inhibitor Retsevmo is expected to be approved, and the commercial product portfolio is expected to increase to 8 products, with a growing product portfolio and a gradual synergy effect
.

In March 2022, the Company and Eli Lilly jointly announced the expansion of the scope of
their long-term partnership.
Cinda Bio acquired the first commercialization rights of Xiranze and Retsevmo in Chinese mainland, as well as the priority negotiation
rights of Pirtobrutinib (BTK Inhibitor) in the future commercialization rights in Chinese mainland 。 In August 2022, the Company and Sanofi jointly announced a strategic collaboration in the field of oncology to accelerate the development and commercialization of two of Sanofi's core core potential first-of-breed tumor pipelines, including: SAR408701 (tusamitamab ravtansine; CEACAM5 ADC) and SAR444245 (non-α-biased IL-2) in clinical phase II, exploring a series of clinical studies
in combination with two drug candidates.
In addition to the product collaboration, Sanofi will make its initial strategic equity investment worth €300 million in Cinda Biologics
.

LUYE

Interim report of Luye Pharmaceutical

Revenue decreased by 3.
4% to profit of $297 million

On September 29, Luye Pharmaceutical Group Co.
, Ltd.
released the first half of 2022 performance report, in the six months ended June 30, 2022, the group's revenue was 2.
8508 billion yuan, a year-on-year decrease of 3.
4%; Net profit attributable to the mother was 297 million yuan, down 23%
year-on-year.

Source: Green Leaf Pharmaceuticals 2022 Interim Report

Product revenue

The 9 main products of Luye Pharmaceutical, lipoline (paclitaxel liposome), Ximena (glycindiazole), Boyono (bevacizumab), Lipidemia, Metona (horse achitonin), Besci (acarbose), Listigmine transdermal patch, Sriken and Srecan extended-release tablets (quetiapine fumarate) and recitral (risperidone oral solution) have established a strong competitive advantage in the field of high incidence of diseases in the world and are expected to maintain the current level
。 During the reporting period, the Group's revenue from cardiovascular system products decreased by 1.
7% to 787.
1 million yuan, digestion and metabolism products revenue of 322.
7 million yuan (-29.
6%), oncology products revenue of 1.
025 billion yuan (+10.
6%), and nervous system products revenue of 651.
7 million yuan (-6.
1%)
.

Source: Green Leaf Pharmaceuticals 2022 Interim Report

R&D process

As of June 30, 2022, Luye Pharmaceutical had 32 products under research in China at different stages of development, including 13 oncology products, 12 central nervous system products and 7 other products
.
In addition, the Group has 13 products
under development in the United States, Europe and Japan at various stages of development.

In January 2022, the application for marketing authorization of oxycodone naloxone extended-release tablets, a product under research of Luye Pharmaceutical, was accepted
by the State Food and Drug Administration.
In March 2022, the Group submitted a marketing application for LY01017 introduced from PharmaMar in Hong Kong, China for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed after receiving chemotherapy with platinum-based drugs; In July, LY01017 was approved for clinical urgent use
in specific medical institutions in the Boao Lecheng Pilot Zone of Hainan.
The Group's self-developed new class 1 drug LY03005 was approved for the treatment of generalized anxiety disorder Phase III clinical trial
in March 2022.
Previously, LY03005 has completed a Phase I.
~III.
clinical trial for the treatment of depression, and the application for listing of this indication was accepted
by the State Food and Drug Administration in June 2022.
In April 2022, the application for the listing of Lindzimite (twice a week) was accepted by the State Food and Drug Administration, and in 2021, it was approved for listing in many European countries, and Kinsey Pharmaceutical was granted the right to
commercialize the product in Chinese mainland.
In May 2022, the Group completed Phase I clinical research
on the Class 1 analgesic drug LPM3480392 developed by the Group in China.
In July 2022, the Chinese phase III clinical trial of rotigotin extended-release microspheres for the treatment of Parkinson's disease reached the preset endpoint; In the same month, the Chinese phase III clinical trial of Goserelin acetate sustained-release microspheres for breast cancer reached the preset endpoint
.
Dula glycopeptide developed by subsidiary Boan Bio has entered the phase III clinical stage
in China.